Cadrenal Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	-4.85	-8.36	-6.71
Depreciation & Amortization	0	0	0
Share-Based Compensation	0.59	0.71	0.93
Other Operating Activities	0.3	4.11	4.58
Operating Cash Flow	-3.95	-3.53	-1.2
Capital Expenditures	-0	-0	-0
Investing Cash Flow	-0	-0	-0
Share Issuance / Repurchase	6.5	12.15	0.01
Debt Issued / Paid	0	-0.25	1.23
Financing Cash Flow	6.5	11.9	1.24
Net Cash Flow	2.54	8.37	0.03
Free Cash Flow	-3.95	-3.53	-1.21
Free Cash Flow Per Share	-0.25	-0.26	-0.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).